Xceleron and Covance enter co-promotional agreement

17-Nov-2006

Xceleron announced a cooperation agreement with Covance in which both companies will make available each others drug development services to their customers. In addition Xceleron and Covance will carry out joint projects on behalf of sponsors and to further the development of new applications.

Xceleron CEO, Professor Colin Garner commented that "this is a strategically important deal for Xceleron. It demonstrates how quickly our technology has moved from being seen as novel and at the edges of drug development to its acceptance as a mainstream part of the drug development process. Covance is a great partner to have and this agreement will add global marketing power to our business; we look forward to working closely with them".

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?